

## Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review

URL:	<a href="https://marketpublishers.com/r/EBC5B77E746EN.html">https://marketpublishers.com/r/EBC5B77E746EN.html</a>
Date:	May 17, 2018
Pages:	51
Price:	US\$ 125.00
ID:	EBC5B77E746EN

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

### Highlights

Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

### Exelixis Inc Key Recent Developments

May 02,2018: Exelixis Reports First Quarter 2018 Financial Results

Apr 09,2018: Exelixis Elects Dr. Maria Freire to Its Board of Directors

Feb 26,2018: Exelixis Reports Fourth Quarter and Full Year 2017 Financial Results

Nov 01,2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update  
Sep 07,2017: Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Table of Content

### SECTION 1 - ABOUT THE COMPANY

Exelixis Inc - Key Facts  
Exelixis Inc - Key Employees  
Exelixis Inc - Key Employee Biographies  
Exelixis Inc - Major Products and Services  
Exelixis Inc - History  
Exelixis Inc - Company Statement  
Exelixis Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### SECTION 2 – COMPANY ANALYSIS

Company Overview  
Exelixis Inc - Business Description  
Exelixis Inc - Corporate Strategy  
Exelixis Inc - SWOT Analysis  
SWOT Analysis - Overview  
Exelixis Inc - Strengths  
Exelixis Inc - Weaknesses  
Exelixis Inc - Opportunities  
Exelixis Inc - Threats  
Exelixis Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Exelixis Inc, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Apr 09, 2018: Exelixis Elects Dr. Maria Freire to Its Board of Directors  
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update  
Sep 07, 2017: Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy  
Aug 02, 2017: Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update  
May 01, 2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update  
Feb 27, 2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update  
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis

### **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

### **LIST OF TABLES**

Exelixis Inc, Key Facts  
Exelixis Inc, Key Employees  
Exelixis Inc, Key Employee Biographies  
Exelixis Inc, Major Products and Services  
Exelixis Inc, History  
Exelixis Inc, Subsidiaries

Exelixis Inc, Key Competitors  
Exelixis Inc, Ratios based on current share price  
Exelixis Inc, Annual Ratios  
Exelixis Inc, Annual Ratios (Cont.1)  
Exelixis Inc, Interim Ratios  
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Exelixis Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## **LIST OF FIGURES**

Exelixis Inc, Performance Chart (2013 - 2017)  
Exelixis Inc, Ratio Charts  
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

## **COMPANIES MENTIONED**

Intercept Pharmaceuticals Inc  
Ignyta Inc  
Genentech Inc  
Eloxx Pharmaceuticals Inc  
Astex Pharmaceuticals Inc  
Array BioPharma Inc

### I would like to order:

**Product name:** Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review  
**Product link:** <https://marketpublishers.com/r/EBC5B77E746EN.html>  
**Product ID:** EBC5B77E746EN  
**Price:** US\$ 125.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/EBC5B77E746EN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**